Tobacco Etch Virus (TEV) protease is a highly specific protease derived from the Tobacco Etch Virus. It is widely used in biotechnology for its ability to cleave fusion proteins at specific recognition sites. The recombinant form of this protease, often referred to as rTEV, is produced in Escherichia coli (E. coli) and has become an invaluable tool in protein purification and structural biology.
TEV protease is a 27 kDa enzyme that recognizes a specific seven-amino-acid sequence: Glu-Asn-Leu-Tyr-Phe-Gln-Gly. The cleavage occurs between the Gln and Gly residues . This high specificity makes TEV protease an excellent choice for removing affinity tags from fusion proteins without affecting the target protein.
Recombinant TEV protease is produced in E. coli and purified using affinity chromatography. However, the wild-type TEV protease has some limitations, such as low solubility, auto-proteolysis, and instability. To address these issues, researchers have introduced several point mutations to improve its stability and solubility . For example, a mutant called TEVp7M, which incorporates seven changes, has shown remarkable purification yields and improved thermal stability .
TEV protease is extensively used in various biotechnological applications, including:
Recent advances in directed evolution have further enhanced the catalytic efficiency of TEV protease. Researchers have developed yeast-based platforms to evolve high-turnover, low-affinity proteases, resulting in variants with improved performance in both yeast and mammalian cells . These advancements hold promise for expanding the utility of TEV protease in various biotechnological and therapeutic applications.